Job Trends
Labor Market Reports
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
The life sciences job market continues to shift. BioSpace’s Q2 2025 U.S. Life Sciences Job Market Report is now available, offering exclusive insights into the latest hiring trends, layoffs, and workforce dynamics across the life sciences industry.
Now Hiring
Looking for a job in oncology? Check out the BioSpace list of nine companies hiring life sciences professionals like you.
Looking for a biopharma job in Boston? Check out the BioSpace list of six companies hiring life sciences professionals like you.
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
THE LATEST
AstraZeneca released positive data from the Phase III THALES trial of Brilinta (ticagrelor) used twice a day with an aspirin.
“We are pleased the committee recognized the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options,” said Axel Hoos, senior vice president and heat of Oncology R&D for GSK.
Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.
Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.
Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.
BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.
Gilead Sciences reported additional data from its Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
A collective of pharmaceutical companies, including Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, has pledged financial support of approximately $1 billion to support the Antimicrobial Resistance Action Fund.
Through the partnership, Takeda will have access to Twist’s “Library of Libraries,” a large phage display library created using precisely defined synthetic DNA sequences to discover unique antibodies to important therapeutic targets including GPCRs.
Foghorn Therapeutics entered into a strategic collaboration with Merck to leverage Foghorn’s Gene Traffic Control platform for cancer therapies.